Company

Alfasigma Reclaims Sulodexide Rights in China – Business Transfer to Add €25 Million in Annual Revenue and Drive 30 % Expansion of Alfasigma China
Alfasigma

Alfasigma Reclaims Sulodexide Rights in China – Business Transfer to Add €25 Million in Annual Revenue and Drive 30 % Expansion of Alfasigma China

Global pharmaceutical company Alfasigma S.p.A. announced that it has signed a business transfer agreement with its Chinese partner, Hong Kong Ease Comfort Medical Investment Management Co., Ltd. (Ease Comfort), under…

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound

Bayer Q3 2026 Sales Reach €10.053 Billion as Pharmaceuticals Division Hits Growth Turning Point – Nubeqa and Kerendia Lead the Rebound

Boehringer Ingelheim Launches AIRWARD Phase III Trial of Verducatib – First Oral DPP1 Inhibitor to Reach Phase III in COPD

Boehringer Ingelheim Launches AIRWARD Phase III Trial of Verducatib – First Oral DPP1 Inhibitor to Reach Phase III in COPD

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Academic conferenceADC / XDC

LaNova’s CLDN18.2 ADC LM-302 Shows 15-Month PFS in Gastric Cancer Phase II Data at ASCO 2026

Alphamab OncologyCancer

Alphamab-CSPC’s HER2 Bispecific Antibody Anbenitamab Wins NMPA Approval for Refractory Gastric Cancer with 75% PFS Benefit

Auto-immuneClinical trial approval / initiation

Lynk Pharmaceuticals Advances Pan-JAK Inhibitor LNK01004 into Phase II for Vitiligo and Hand Eczema with Skin-Restricted Design

CF PharmTechClinical trial approval / initiation

CF PharmTech’s Inhaled siRNA Therapy ICF004 Receives NMPA Clinical Approval for Interstitial Lung Disease

Show More